Drugs / NEO100
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06357377 | Jan → Oct 2026 expected | childhood choroid plexus carcinoma, childhood spinal cord tumor, diffuse midline glioma, H3 K27M-mutant, pineocytoma | Neonc Technologies, Inc. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05023018 | Jul 2022 → Dec 2026 expected | meningioma | Neonc Technologies, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-08-12 | Neonc Technologies, Inc. | Results NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma neonc.com ↗ |
| 2026-06-23 | Neonc Technologies, Inc. | Regulatory NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone neonc.com ↗
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO100, the Company’s lead candidate, an intranasally administered formulation of purified perillyl alcohol designed for non-invasive nose-to-brain delivery. |
| 2025-12-17 | Neonc Technologies, Inc. | Results NeOnc Technologies Reports Updated Clinical Results neonc.com ↗
Updated results demonstrate that treatment with intranasally delivered NEO100 has resulted in significant radiographic remission in 6 of 25 patients (24%), representing 3X increase over the 8% response rates typically reported with salvage therapies in recurrent high-grade gliomas. |
| 2025-12-01 | Neonc Technologies, Inc. | Results NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors neonc.com ↗
The study, now available on bioRxiv (https://www.biorxiv.org/content/10.1101/2025.11.25.690556v1), demonstrates that ultrasound further enhances and amplifies NEO100’s therapeutic potency, driving strong antitumor effects across multiple primary and metastatic brain tumor types. |
| 2025-11-12 | Neonc Technologies, Inc. | Results NeOnc Technologies Reports Updated Clinical Results neonc.com ↗ |
| 2025-03-31 | Neonc Technologies, Inc. | Regulatory NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 neonc.com ↗
Receiving the Rare Pediatric Disease Designation for NEO100 is a crucial step forward in our mission to develop effective treatments for children facing diffuse high-grade gliomas,” said Dr. Thomas Chen, CEO and Chief Science Officer of NeOnc Technologies Holdings, Inc. |
All press releases naming this drug 16 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEO100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05023018 ↗ |
| Known as | perillyl alcohol | “NEO100 is a purified form (\>98.5%) of the naturally occurring monoterpene perillyl alcohol.” NCT06357377 ↗1“NEO100 is a purified form of perillyl alcohol.” NCT05023018 ↗ |
| Modality | Small molecule | “naturally occurring monoterpene perillyl alcohol” NCT06357377 ↗ |
| Route | Intranasal | “Intranasal delivery of NEO100 will directly penetrate meningiomas, particularly skull-based meningiomas which extend along the olfactory groove, tuberculum sella, spenoid ridge...” NCT05023018 ↗ |